Document Detail

Clinical pharmacology, biomarkers and personalized medicine: education please.
MedLine Citation:
PMID:  20477707     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Over the past decades, the scope of clinical pharmacology within the pharmaceutical industry has widened considerably. Key growth has been in the area of translational science and exploratory medicine, where clinical pharmacologists are nowadays the mediator between basic research and establishment of clinical usefulness. This role has led to and is supported by the rapid developments in pharmacokinetic-pharmacodynamic modeling and simulation, a strong focus on biomarkers for early informed decision-making, and the advent of pharmacogenomics into safety and efficacy predictions and evaluations. The ultimate goal--safer, more efficacious drug prescription--is shared with that of today's drive for more personalized medicine. This article reviews the evolution of clinical pharmacology within the industry, the regulatory, clinical and societal drivers for this evolution, and the analogy with the establishment of personalized medicine in clinical practice. Special attention is given to the integration of biomarkers into clinical practice and the concurrent need for education of clinicians, pharmacists, payers and patients.
Paul de Koning; James Keirns
Related Documents :
21616017 - Better knowledge, better health: piloting an education intervention in chronic conditio...
25296627 - Primary corneal melanocytoma in a collie.
19719037 - Managing venous thromboembolic events in daily practice: "time is never enough".
19619687 - The interpretation of clinical trial data--wrongly acclaim'ed?
20359677 - Pediatric rehabilitation: 1. common medical conditions in children with disabilities.
24046937 - A summarized discussion of current good manufacturing practice regulations.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Biomarkers in medicine     Volume:  3     ISSN:  1752-0371     ISO Abbreviation:  Biomark Med     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2010-05-18     Completed Date:  2010-06-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101312535     Medline TA:  Biomark Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  685-700     Citation Subset:  -    
Exploratory Development Department, Astellas Pharma Global Development-Europe, Elisabethhof 1, 2353 EW Leiderdorp, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical pharmacology: a paradigm for individualized medicine.
Next Document:  Personalized healthcare: how to improve outcomes by increasing benefit and decreasing risk through t...